MedTrace Logo

Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study

NCT04424888 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-12-08

Study results available
· View outcomes & findings →

Summary

This 5-week, double-blind, placebo-controlled, 2x2 crossover pilot study investigate the potential of collecting robust, real-time clinical study measures of glucose levels using Abbott Freestyle Libre Continuous Glucose Monitoring devices associated with a smartphone application

Conditions

Interventions

OTHER

WB-011

WB-011 medical food product.

OTHER

Placebo

Placebo Capsules identical to those containing WB-011.

DEVICE

Continuous Glucose Monitor

Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.

Sponsors & Collaborators

  • Pendulum Therapeutics

    lead INDUSTRY

Principal Investigators

  • Chief Technical Officer, PhD · Pendulum Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-15
Primary Completion
2018-04-29
Completion
2018-06-29
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04424888 on ClinicalTrials.gov